The integrated Phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine

International Journal of Infectious Diseases

Volumn 11, Issue SUPPL. 2, 2007, Pages

  Dennehy, Penelope H ^a   Goveia, Michelle G ^b   Dallas, Michael J ^b   Heaton, Penny M ^c  

^a BROWN UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NOVAVAX INC   (United States)

Author keywords

Pentavalent rotavirus vaccine; Rotavirus; Safety; Vaccine

Indexed keywords

PENTAVALENT ROTAVIRUS VACCINE; PLACEBO; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

BRONCHIOLITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIAGNOSTIC VALUE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ELECTRODIAGNOSIS; ELECTROPHEROTYPING; FEMALE; FEVER; GASTROENTERITIS; HUMAN; HUMAN EXPERIMENT; INFANT; INTUSSUSCEPTION; IRRITABILITY; MALE; MEDICAL RECORD; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; ROTAVIRUS; ROTAVIRUS WC3; SIDE EFFECT; VACCINATION; VIRAL GASTROENTERITIS; VIRUS CULTURE; VIRUS SHEDDING; VIRUS TRANSMISSION; VIRUS TYPING; VOMITING;

COHORT STUDIES; FECES; FEMALE; GASTROENTERITIS; HUMANS; INFANT; INTUSSUSCEPTION; MALE; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VIRUS SHEDDING;

EID: 34748911926     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(07)60020-4     Document Type: Review

References (11)

1. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine - United States. 1998-1999. MMWR 48 (1999) 577-581
2. Vesikari T., Clark H., Offit P., Dallas M., DiStefano D., Goveia M., et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 24 (2006) 4821-4829
3. Vesikari T., Matson D., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
4. Block S., Vesikari T., Goveia M., Rivers S., Adeyi B., Dallas M., et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 119 1 (2007) 11-18
5. Dolan K., Twist E., Horton-Slight P., Forrer C., Bell Jr. L., Plotkin S., et al. Epidemiology of rotavirus electrophenotypes determined by a simplified diagnostic technique with RNA analysis. J Clin Microbiol 21 (1985) 753-758
6. Rennels M., Parashar U., Holman R., Le C., Chang H., and Glass R. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J 17 (1998) 924-925
7. Murphy T., Gargiullo P., Massoudi M., Nelson D., Jumaan A., Okoro C., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 (2001) 564-572
8. Parashar U., Hummelman E., Bresee J., Miller M., and Glass R. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9 (2003) 565-572
9. RotaShield [prescribing information]. Wyeth-Ayerst Laboratories, Philadelphia, PA 19101. August 27, 1998.
10. Ciarlet M., and Estes M. Rotaviruses: basic biology, epidemiology and methodologies. In: Bitton G. (Ed). Encyclopedia of Environmental Microbiology (2002), Wiley, New York, NY 2753-2773
11. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Record of the Proceedings. June 27-28, 2007.